Publicacións en colaboración con investigadores/as de Hospital de Cabueñes (11)

2023

  1. SEOM SOGUG clinical guideline for treatment of kidney cancer (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2732-2748

2018

  1. Outcomes of single versus double hormone receptor–positive breast cancer. A GEICAM/9906 sub-study

    European Journal of Cancer, Vol. 94, pp. 199-205

  2. Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy

    Clinical and Translational Oncology, Vol. 20, Núm. 12, pp. 1548-1556

2017

  1. A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624

2015

  1. Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice

    Clinical and Translational Oncology, Vol. 17, Núm. 11, pp. 862-869

2014

  1. Breast cancer management in the elderly

    Clinical and Translational Oncology, Vol. 16, Núm. 4, pp. 351-361

2012

  1. First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients

    Expert Opinion on Pharmacotherapy, Vol. 13, Núm. 10, pp. 1389-1396

2011

  1. A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)

    Investigational New Drugs, Vol. 29, Núm. 5, pp. 1038-1044

  2. Management of patients with metastatic breast cancer

    Advances in Therapy, Vol. 28, Núm. SUPPL. 6, pp. 50-65

2010

  1. Novel therapeutic approaches to the treatment of metastatic breast cancer

    Cancer Treatment Reviews, Vol. 36, Núm. 1, pp. 33-42

2008

  1. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer

    Journal of the National Cancer Institute, Vol. 100, Núm. 11, pp. 805-814